Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

Cancer

Volumn 119, Issue 21, 2013, Pages 3788-3796

  Shanafelt, Tait ^a   Lanasa, Mark C ^b   Call, Timothy G ^a   Beaven, Anne W ^b   Leis, Jose F ^a   Laplant, Betsy ^a   Bowen, Deborah ^a   Conte, Michael ^a   Jelinek, Diane F ^a   Hanson, Curtis A ^a   Kay, Neil E ^a   Zent, Clive S ^a  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

chemoimmunotherapy; chronic lymphocytic leukemia; fludarabine; ofatumumab; pentostatin; rituximab; small lymphocytic lymphoma; treatment

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; OFATUMUMAB; PENTOSTATIN; RITUXIMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; CANCER GROWTH; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEMOLYSIS; HUMAN; IMMUNOCHEMOTHERAPY; IMMUNOTHERAPY; INFECTION; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; RETREATMENT; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT RESPONSE;

CHEMOIMMUNOTHERAPY; CHRONIC LYMPHOCYTIC LEUKEMIA; FLUDARABINE; OFATUMUMAB; PENTOSTATIN; RITUXIMAB; SMALL LYMPHOCYTIC LYMPHOMA; TREATMENT;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PENTOSTATIN; TREATMENT OUTCOME;

EID: 84886099199     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28292     Document Type: Article

References (31)

1. Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1750-1757.
2. Johnson S, Smith AG, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996; 347: 1432-1438.
3. Leporrier M, Chevret S, Cazin B, et al; French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001; 98: 2319-2325.
4. Flinn I, Kumm E, Grever M, et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial 2997 [Abstract]. Blood. 2004; 104: Abstract 475.
5. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107: 885-891.
6. Catovsky D, Richards S, Matutes E, et al. Fludarabine plus cyclophosphamide improves response and progression-free survival in chronic lymphocytic leukemia. A report from the LRF CLL4 Trial. Lancet. 2007; 370: 230-239.
7. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174.
8. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30: 980-988.
9. Ferrajoli A, O'Brien SM, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma. 2005; 46: 587.
10. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010; 28: 1749-1755.
11. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177: 362-371.
12. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 2165-2170.
13. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001; 19: 2153-2164.
14. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011; 118: 5126-5129.
15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456.
16. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21: 956-964.
17. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1910-1916.
18. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007; 109: 405-411.
19. Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013; 121: 4137-4141.
20. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101: 6-14.
21. Gerrie AS, Toze CL, Ramadan KM, et al. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leuk Lymphoma. 2012; 53: 77-82.
22. Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011; 117: 6450-6458.
23. Keating M, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4079-4088.
24. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004; 199: 1659-1669.
25. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001; 98: 2771-2777.
26. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001; 98: 3383-3389.
27. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011; 117: 4519-4529.
28. Rafiq S, Butchar JP, Cheney C, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013; 190: 2702-2711.
29. Norin S, Kimby E, Lundin J,. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. Med Oncol. 2010; 27: 820-825.
30. Blum KA, Young D, Broering S, et al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol. 2007; 25: 5624-5629.
31. Eichhorst BF, Fischer K, Fink AM, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011; 117: 1817-1821.